Albireo Reports Fourth Quarter and Year-End 2017 Financial Results

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

“2017 was significant for Albireo, as we completed a successful Phase 2 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor, in children with cholestatic liver disease and pruritus and, following engagement with both the FDA and EMA, designed a Phase 3 program for A4250 for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC) that we plan to initiate this spring,” said Ron Cooper, President and Chief Executive Officer of Albireo.

Click here to read the full press release.